A Study of Galcanezumab in Participants With Chronic Cluster Headache
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic cluster headache.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: Placebo
- drug: Galcanezumab 300 mg
Eligibility
Inclusion Criteria:
- Participants with a history of chronic cluster headache occurring without a remission
period, or with remissions lasting <1 month, for at least 1 year.
- Participants are able to distinguish cluster headache attacks from other headaches.
Exclusion Criteria:
- Current enrollment in or discontinuation within the last 30 days from, a clinical
trial involving any investigational drug or device.
- Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP)
antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF).
- Are taking indomethacin and/or are suspected of having another distinct trigeminal
autonomic cephalalgia.
- A history of migraine variants that could implicate or could be confused with
ischemia.
- Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
proteins.
- A history or presence of other medical illness that indicates a medical problem that
would preclude study participation.
- Evidence of significant active or unstable psychiatric disease, in the opinion of the
investigator.
- Women who are pregnant or nursing.
Ages Eligible for Study
18 Years - 65 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
650-723-5184
Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.